Vaccinex Rallies After Announcing Multi-Project Pact Using Its Antibody Discovery PlatformBenzinga • 02/19/21
Vaccinex Announces Signing of Two Multi-Project Deals with Leading Pharmaceutical Companies Focused on Leveraging Its ActivMAb® PlatformGlobeNewsWire • 02/19/21
Vaccinex to Participate in the LifeSci Partners 10th Annual Healthcare Corporate Access EventGlobeNewsWire • 01/05/21
Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 11/13/20
CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical ConferenceGlobeNewsWire • 10/29/20
Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical ConferenceGlobeNewsWire • 10/29/20
Vaccinex's stock falls after investigational drug fails Huntington's disease studyMarket Watch • 09/22/20
Top-Line Results of Phase 2 SIGNAL Study in Huntington’s Disease Support Potential for Cognitive Benefit of PepinemabGlobeNewsWire • 09/22/20
Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaGlobeNewsWire • 09/17/20
Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 08/14/20
Vaccinex, Inc. (VCNX) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 08/05/20
Vaccinex Provides Update of Potentially Pivotal SIGNAL Clinical Trial in Huntington’s DiseaseGlobeNewsWire • 07/07/20
Vaccinex Reports First Quarter 2020 Financial Results and Provides Corporate UpdateGlobeNewsWire • 05/14/20